Status:
ACTIVE_NOT_RECRUITING
Exploring the Utility of [18F]3F4AP for Demyelination Imaging in Controls, Neurodegeneration and Traumatic Brian Injury
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Brain Injuries, Traumatic
Demyelinating Disorder
Eligibility:
All Genders
18-90 years
Phase:
PHASE1
Brief Summary
The overall objective is to obtain an initial assessment of the value of using \[18F\]3F4AP for imaging demyelinating diseases such as traumatic brain injury (TBI), neurodegenerative diseases such as ...
Eligibility Criteria
Inclusion
- Subjects are 18 years of age and older, except AD subjects who are 60 to 90 years of age.
Exclusion
- A subject will not be eligible for inclusion in this study if any of the exclusion criteria for PET/CT or MRI studies applies. A negative STAT quantitative serum hCG pregnancy test is required on the day of the PET/CT scan before female subjects of childbearing potential can participate. Any woman of childbearing potential, who is seeking to become pregnant, is breastfeeding, or who suspects she may be pregnant will not be enrolled in the study.
Key Trial Info
Start Date :
January 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2025
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04710550
Start Date
January 25 2021
End Date
December 1 2025
Last Update
January 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114